SCHEMBL22657488

SCHEMBL22657488

O=CCc1c(F)cc(N2CCOCC2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.42
MYC P01106 1/20 0.41
WDR5 P61964 1/20 0.41
LMNA P02545 3/20 0.41
PRKDC P78527 2/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
RAD51 Q06609 2/20 0.38
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GPR183 P32249 1/20 0.37
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22657531 0.85 ALDH1A1 (0.40) LMNAKDM4EMEN1ALDH1A1KMT2A
SCHEMBL22657477 0.83 ALDH1A1 (0.41) LMNAKDM4EMEN1ALDH1A1KMT2A
SCHEMBL7161474 0.81 PRKDC (0.55) LMNAPRKDCPIK3CDPIK3CAPIK3CB
SCHEMBL6629681 0.79 GPR183 (0.44) AKR1C3LMNAPRKDCPIK3CDPIK3CA
SCHEMBL6225482 0.78 PRKDC (0.47) LMNAPRKDCPIK3CDPIK3CAPIK3CB
SCHEMBL28991001 0.78 KDM4E (0.42) AKR1C3MYCWDR5LMNAKDM4E
SCHEMBL19861027 0.78 KDM4E (0.46) AKR1C3MYCWDR5LMNAKDM4E
SCHEMBL21495036 0.78 KDM4E (0.41) AKR1C3LMNAPRKDCPIK3CDPIK3CA
SCHEMBL1701348 0.75 PIK3CD (0.51) LMNAPRKDCPIK3CDPIK3CAPIK3CB
SCHEMBL28123984 0.75 PRKDC (0.48) AKR1C3MYCWDR5LMNAPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 EP disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 CN disclosed
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2022-07-07 US disclosed
EP-3966199-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2022-03-16 EP disclosed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 CN disclosed
WO-2020229968-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2020-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA AKR1C3 2991/4885MYC 3791/4885WDR5 2824/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 AKR1C3 2527/4885MYC 3640/4885WDR5 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.